Physician profile
Devashish Sen
NPI 1710959986
$2,475.80
in general payments reported to CMS, 2019-2025
14 companies · $396 in 2025
The $396 reported for 2025 was more than what 75% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $260 · 2021: $215 · 2022: $122 · 2023: $733 · 2024: $319 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,447.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,337.83 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Medtronic, INC. | $326.81 | 2022-2023 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.91 | 2023-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $109.95 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $106.01 | 2025 | |
| Horizon Therapeutics Plc | $93.22 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $79.04 | 2021-2024 | Xtampza, Belbuca |
| Merz Pharmaceuticals, LLC | $65.85 | 2024-2025 | Xeomin |
| Abbott Laboratories | $54.83 | 2020-2025 | Proclaim |
| Nevro Corp. | $49.99 | 2020 | |
| Amgen INC. | $33.70 | 2020 | |
| Ibsa Pharma INC. | $19.80 | 2023 | Tirosint, Licart |
| Tonix Medicines, INC. | $19.80 | 2025 | Tonmya |
| Avanos Medical | $15.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devashish Sen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.